“困扰评分”在有症状良性前列腺增生评估与治疗中的有效性
Validity of the "bother score" in the evaluation and treatment of symptomatic benign prostatic hyperplasia.
作者信息
O'leary Michael P
出版信息
Rev Urol. 2005 Winter;7(1):1-10.
Abstract
Benign prostatic hyperplasia (BPH) is a condition that is common among older men. It causes a variety of clinically significant lower urinary tract signs and symptoms. BPH is rarely life-threatening; the decision to seek treatment is frequently based on the degree to which patients find the symptoms bothersome and disruptive of daily activities. Recently developed reliable and valid outcome measures to evaluate treatments for BPH are clinical tools that urologists can use to determine the extent of bother and make treatment decisions. A single question used to determine the "bother score" provides a widely used and statistically valid measure of the need for treatment of BPH. Validation data support the argument that the bother score is a statistically reliable measure of treatment outcome in patients with BPH who view their symptoms as bothersome.
摘要
良性前列腺增生（BPH）是一种在老年男性中常见的病症。它会引发多种具有临床意义的下尿路症状和体征。BPH很少危及生命；是否寻求治疗的决定通常取决于患者认为症状对日常生活造成困扰和干扰的程度。最近开发的用于评估BPH治疗效果的可靠且有效的结局指标是泌尿科医生可用于确定困扰程度并做出治疗决策的临床工具。一个用于确定“困扰评分”的单一问题提供了一种广泛使用且在统计学上有效的衡量BPH治疗需求的方法。验证数据支持这样的观点，即困扰评分是在那些认为自身症状令人困扰的BPH患者中，对治疗结果进行统计学可靠衡量的指标。
相似文献
1
Validity of the "bother score" in the evaluation and treatment of symptomatic benign prostatic hyperplasia.
Rev Urol. 2005 Winter;7(1):1-10.
2
Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.
Drugs Today (Barc). 2007 Jun;43 Suppl B:1-7.
3
Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
BJU Int. 2009 Oct;104(7):974-83. doi: 10.1111/j.1464-410X.2009.08503.x. Epub 2009 May 7.
4
Impact of symptoms of prostatism on level of bother and quality of life of men in the French community.
J Urol. 1995 Mar;153(3 Pt 1):669-73. doi: 10.1097/00005392-199503000-00033.
5
Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH.
BJU Int. 2005 Mar;95(4):571-4. doi: 10.1111/j.1464-410X.2005.05341.x.
6
Use of Structural Equation Modeling to Demonstrate the Differential Impact of Storage and Voiding Lower Urinary Tract Symptoms on Symptom Bother and Quality of Life during Treatment for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
J Urol. 2016 Sep;196(3):824-30. doi: 10.1016/j.juro.2016.04.062. Epub 2016 Apr 19.
7
Comprehensive patient evaluation for benign prostatic hyperplasia.
Urology. 1998 Apr;51(4A Suppl):13-8. doi: 10.1016/s0090-4295(98)00050-8.
8
[Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
Prog Urol. 2015 Jun;25(7):404-12. doi: 10.1016/j.purol.2015.02.008. Epub 2015 Apr 2.
9
Survey of overactive bladder symptoms influencing bother before and after treatment with tamsulosin hydrochloride in Japanese patients with benign prostatic hyperplasia.
Urology. 2011 Nov;78(5):1058-62. doi: 10.1016/j.urology.2011.05.032. Epub 2011 Sep 9.
引用本文的文献
1
Imaging for Hemorrhoidal Disease: Navigating Rectal Artery Embolization from Planning to Follow-up.
Semin Intervent Radiol. 2024 Aug 19;41(3):263-269. doi: 10.1055/s-0044-1788056. eCollection 2024 Jun.
2
Sleep quality and obstructive sleep apnea among male patients with lower urinary tract symptoms: A prospective observational study.
Indian J Urol. 2024 Jan-Mar;40(1):56-61. doi: 10.4103/iju.iju_325_23. Epub 2023 Dec 29.
3
Triptorelin therapy for lower urinary tract symptoms (LUTS) in prostate cancer patients: A systematic meta-analysis.
BJUI Compass. 2023 Oct 10;5(1):17-28. doi: 10.1002/bco2.292. eCollection 2024 Jan.
4
Lower urinary tract symptom severity, urinary bother, and incident life-space mobility restriction among older men.
J Am Geriatr Soc. 2023 Apr;71(4):1093-1104. doi: 10.1111/jgs.18171. Epub 2022 Dec 15.
5
IPSS "bother question" score predicts health-related quality of life better than total IPSS score.
World J Urol. 2022 Mar;40(3):765-772. doi: 10.1007/s00345-021-03911-2. Epub 2022 Jan 9.
6
Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
AAPS J. 2021 Feb 25;23(2):33. doi: 10.1208/s12248-021-00568-y.
7
Integrated Item Response Theory Modeling of Multiple Patient-Reported Outcomes Assessing Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
AAPS J. 2020 Jul 29;22(5):98. doi: 10.1208/s12248-020-00484-7.
8
Assessing health-related quality of life in urology - a survey of 4500 German urologists.
BMC Urol. 2017 Jun 19;17(1):46. doi: 10.1186/s12894-017-0235-1.
9
Lack of Patient-Clinician Concordance in Cancer Patients: Its Relation With Patient Variables.
J Pain Symptom Manage. 2017 Jun;53(6):988-998. doi: 10.1016/j.jpainsymman.2016.12.347. Epub 2017 Feb 6.
10
Nocturia and overnight polysomnography in Parkinson disease.
Neurourol Urodyn. 2013 Nov;32(8):1080-5. doi: 10.1002/nau.22365. Epub 2013 Jan 28.
本文引用的文献
1
Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).
Eur Urol. 2003 Dec;44(6):637-49. doi: 10.1016/j.eururo.2003.08.015.
2
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
BJU Int. 2003 Aug;92(3):257-61. doi: 10.1046/j.1464-410x.2003.04309.x.
3
Symptom-specific quality of life in patients with benign prostatic hyperplasia.
Int J Urol. 2002 Sep;9(9):485-90. doi: 10.1046/j.1442-2042.2002.00503.x.
4
Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Urology. 2001 Dec;58(6):953-9. doi: 10.1016/s0090-4295(01)01448-0.
5
Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions.
Pharmacoeconomics. 2001;19(11):1079-90. doi: 10.2165/00019053-200119110-00002.
6
Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy.
J Clin Hypertens (Greenwich). 2001 Jul-Aug;3(4):218-23. doi: 10.1111/j.1524-6175.2001.00459.x.
7
Benign prostatic hyperplasia. Patient evaluation and relief of obstructive symptoms.
Geriatrics. 2001 Mar;56(3):33-8.
8
A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.
BJU Int. 2001 Feb;87(3):192-200. doi: 10.1046/j.1464-410x.2001.02032.x.
9
LUTS, ED, QOL: alphabet soup or real concerns to aging men?
Urology. 2000 Nov 1;56(5 Suppl 1):7-11. doi: 10.1016/s0090-4295(00)00742-1.
10
Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA).
Oncology (Williston Park). 2000 Feb;14(2):267-72, 277-8, 280 passim.
Zotero 插件